Genelabs Technologies Inc. said the U.S. Food and Drug Administration has asked for additional Phase III clinical trial of its experimental lupus drug Prestara.
The company, in a news release, said the FDA stated that additional positive clinical data would be necessary before it considers a review.
Shares of Genelabs were down 15 percent to $1.52 in premarket trading on the Inet, after closing at $1.79 on the Nasdaq.